NCT01993641已完成2 期
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 21
- 主要终点
- Estimate clinical improvement
研究概览
简要总结
The purpose of this open label study is to determine whether combining pracinostat (study drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in Myelodysplastic Syndrome (MDS) patients who have failed an initial single agent hypomethylating agent (HMA), and to provide additional safety and efficacy data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent
- •Histologically or cytologically documented diagnosis of MDS (any French-American-British classification [FAB] subtype)
- •Bone marrow blasts >5% and <30% and a peripheral white blood cell (WBC) count of <20,000 /µL
- •Bone marrow biopsy, aspirates, and peripheral blood smears within 28 days of first study treatment
- •Primary failures: Progression after their most recent HMA therapy according to IWG criteria after receiving single agent azacitidine and/or single agent decitabine, or has worsening cytopenias (increased transfusion requirement), increased BM blasts, progression to a higher FAB type, or develops additional clinically significant cytogenetic abnormalities; Secondary failures: Relapse after any initial CR, PR, HI, or development of clinically significant cytogenetic abnormalities at any time according to IWG criteria after receiving single agent azacitidine or decitabine
- •Failure to achieve a response (any CR, PR or HI) according to IWG criteria definition of stable disease after the most recent HMA therapy (at least 6 cycles of azacitidine or 4 cycles of decitabine)
- •Must have demonstrated tolerability to single agent HMA
- •Able to start combination therapy within 3 months of the last single agent HMA dose with no other therapy for disease under study received during this interval
- •Not a candidate for hematopoietic stem cell transplant within 4 months of screening
- •ECOG performance status of 0, 1, or 2
- •Adequate organ function as evidenced by:
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x the upper limit of normal (ULN)
- •Total bilirubin ≤1.5 x ULN or total bilirubin of ≤2 mg/dL, whichever is higher
- •Serum creatinine <2 mg/dL, or creatinine clearance ≥60 mL/min
- •QTcF interval ≤470 msec
- •Female or male patients ≥18 years-of-age
- •Male patients with female partners are required to use two forms of acceptable contraception; Female patients of childbearing potential must have a negative pregnancy test ≤7 days before first study treatment.
- •Willingness and ability to understand the nature of this trial and to comply
排除标准
- •Received any of the following within the specified time frame after the last single agent HMA dose until the first administration of study medication:
- •Any therapy for malignancy between the time of single agent HMA and first on-study treatment
- •Hydroxyurea within 48 hours prior to first study treatment
- •Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or thrombopoietin receptor agonists within 7 days (14 days for Aranesp) prior to first study treatment
- •Major surgery within 28 days of study day 1
- •Patients who are candidates for aggressive chemotherapy (e.g. typical AML induction therapy)
- •Cardiopulmonary function criteria:
- •Current unstable arrhythmia requiring treatment
- •History of symptomatic congestive heart failure (New York Heart Association Class III or IV)
- •History of myocardial infarction within 6 months of enrollment
- •Current unstable angina
- •Concomitant treatment with agents that have activity against HDAC inhibitors is not permitted
- •Clinical evidence of CNS involvement
- •Patients with gastrointestinal (GI) tract disease, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)
- •Active infection with human immunodeficiency virus or chronic hepatitis B or C
- •Life-threatening illness unrelated to cancer or any serious medical or psychiatric illness that could potentially interfere with participation in this study
- •Presence of a malignant disease within the last 12 months, with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or non-melanomatous skin cancer and other concurrent malignancies will be considered on a case by case basis
- •Inability or unwillingness (including psychological, familial, sociological, or geographical conditions) to comply
研究组 & 干预措施
Pracinostat added to HMA
Experimental
Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
干预措施: pracinostat (Drug)
Pracinostat added to HMA
Experimental
Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
干预措施: Azacitidine (Drug)
Pracinostat added to HMA
Experimental
Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
干预措施: Decitabine (Drug)
结局指标
主要结局
Estimate clinical improvement
时间窗: 6 months
Clinical Improvement Rate defined as the proportion of patients with CR, Marrow CR, PR, and HI.
次要结局
- Estimate Overall Response Rate (ORR), including all Complete and Partial Responses, Marrow CR, HI, SD, transfusion independence, and cytogenetic responses(6 months)
- Estimate Complete Response (CR) rate(6 months)
- Estimate Event Free Survival (EFS)(12 months)
- Estimate Overall Survival (OS)(6-24 months)
- Estimate Marrow CR rate(6 months)
- Estimate Stable Disease (SD) rate(6 months)
- Estimate Cytogenetic Response rate(6 months)
- Estimate Hematologic Improvement (HI) rate(6 months)
- Estimate Duration of Response (DoR)(6 months)
- Estimate Progression Free Survival (PFS)(6-12 months)
- Assess the safety profile of the combination(12 months)
- Assess transfusion independence(6 months)
研究者
研究点 (21)
Loading locations...
相似试验
已完成
1 期
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult SubjectsVolunteersHealthy VolunteersHuman VolunteersNormal VolunteersNCT02922933Syndax Pharmaceuticals66
撤回
2 期
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerCancer of the Bile DuctGallbladder CancerNCT00386516Galectin Therapeutics Inc.
终止
2 期
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal InfectionCryptococcal Infection DisseminatedNCT01562132Yale University6
已完成
1 期
A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy VolunteersHealthy VolunteerNCT01814709Genentech, Inc.32
已完成
2 期
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeBipolar Disorder IBipolar Disorder IIMajor Depressive EpisodeNCT03692910Biogen35